tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

CABA Stock Latest News

Cabaletta Bio Announces $94 Million Public Offering
Company AnnouncementsCabaletta Bio Announces $94 Million Public Offering
11d ago
8K
CABA
Promising Clinical Data and Positive Trajectory Support Buy Rating for Cabaletta Bio
PremiumRatings
Promising Clinical Data and Positive Trajectory Support Buy Rating for Cabaletta Bio
11d ago
CABA
Promising Clinical Data from Cabaletta Bio’s RESET Trial Supports Buy Rating
PremiumRatings
Promising Clinical Data from Cabaletta Bio’s RESET Trial Supports Buy Rating
11d ago
CABA
Promising Efficacy and Strategic Advancements: Douglas Tsao’s Buy Rating on Cabaletta Bio
PremiumRatings
Promising Efficacy and Strategic Advancements: Douglas Tsao’s Buy Rating on Cabaletta Bio
11d ago
CABA
Cabaletta presents ‘promising’ results across indications, says H.C. Wainwright
PremiumThe Fly
Cabaletta presents ‘promising’ results across indications, says H.C. Wainwright
11d ago
CABA
Cabaletta Bio Ends Sales Agreement with TD Securities
PremiumCompany AnnouncementsCabaletta Bio Ends Sales Agreement with TD Securities
12d ago
8K
CABA
Cabaletta Bio announces offering of common stock, warrants, no amount given
Premium
The Fly
Cabaletta Bio announces offering of common stock, warrants, no amount given
12d ago
CABA
Cabaletta Bio reports data from the RESET trials evaluating rese-cel
Premium
The Fly
Cabaletta Bio reports data from the RESET trials evaluating rese-cel
12d ago
CABA
Cabaletta Bio Stockholders Approve Key Proposals
PremiumCompany Announcements
Cabaletta Bio Stockholders Approve Key Proposals
13d ago
8K
CABA
Cabaletta Bio Reprices Stock Options to Motivate Staff
PremiumCompany Announcements
Cabaletta Bio Reprices Stock Options to Motivate Staff
1M ago
8K
CABA
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
1M ago
ACAD
AFMD
Cabaletta Bio: Hold Rating Amid Cash Constraints and Regulatory Challenges
PremiumRatings
Cabaletta Bio: Hold Rating Amid Cash Constraints and Regulatory Challenges
1M ago
CABA
Cabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating
PremiumRatingsCabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating
1M ago
CABA
Cabaletta Bio price target lowered to $13 from $17 at Citi
Premium
The Fly
Cabaletta Bio price target lowered to $13 from $17 at Citi
1M ago
CABA
Cabaletta Bio’s Strong Financial Position and Strategic Clinical Progress Justify Buy Rating
Premium
Ratings
Cabaletta Bio’s Strong Financial Position and Strategic Clinical Progress Justify Buy Rating
1M ago
CABA
Cabaletta Bio price target raised to $25 from $23 at Guggenheim
PremiumThe Fly
Cabaletta Bio price target raised to $25 from $23 at Guggenheim
1M ago
CABA
Cabaletta Bio Announces 2027 BLA Plans for Rese-cel
PremiumCompany Announcements
Cabaletta Bio Announces 2027 BLA Plans for Rese-cel
1M ago
8K
CABA
Cabaletta Bio announces plans for anticipated 2027 rese-cel BLA submission
PremiumThe Fly
Cabaletta Bio announces plans for anticipated 2027 rese-cel BLA submission
1M ago
CABA
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases
PremiumCompany Announcements
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases
3M ago
CABA
Cabaletta Bio’s Clinical Progress and Strategic Direction Bolster Buy Rating
PremiumRatingsCabaletta Bio’s Clinical Progress and Strategic Direction Bolster Buy Rating
3M ago
CABA
Cabaletta Bio price target lowered to $7 from $10 at UBS
Premium
The Fly
Cabaletta Bio price target lowered to $7 from $10 at UBS
3M ago
CABA
Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating
Premium
Ratings
Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating
3M ago
CABA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >